www.chiesigroup.com Guest

The Group also pays a lot of attention to patient treatment and assistance for those affected by special care diseases which put patient survival at serious risk. We are concentrating our efforts in this direction because we consider it strategic for the future and know it is of great social impact. Aside from our historical commitment to treating neonatal Respiratory Distress Syndrome (RDS), an area in which the Curosurf surfactant has become the reference standard on a worldwide level, Chiesi is turning its attention to other respiratory diseases for newborns, such as apnea in premature infants and bronchopulmonary dysplasia (BPD).

One of the Group’s goals is to offer the medical and scientific communities new therapeutic options in treating serious genetic diseases such as cystic fibrosis. There have been two initial steps in this direction: the first was the launch of Bramitob for the treatment of infections caused by Pseudomonas aeruginosa in patients with cystic fibrosis, and the second was to initiate a joint process with physicians and associations on how to improve the management of patients affected by the disease.